Express Scripts Holding Co (ESRX) Shares Sold by HBK Sorce Advisory LLC
HBK Sorce Advisory LLC trimmed its holdings in shares of Express Scripts Holding Co (NASDAQ:ESRX) by 18.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,832 shares of the company’s stock after selling 652 shares during the quarter. HBK Sorce Advisory LLC’s holdings in Express Scripts were worth $269,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Alps Advisors Inc. increased its position in Express Scripts by 10.5% in the second quarter. Alps Advisors Inc. now owns 13,019 shares of the company’s stock worth $1,005,000 after buying an additional 1,238 shares during the last quarter. CIBC World Markets Inc. increased its position in Express Scripts by 43.5% in the second quarter. CIBC World Markets Inc. now owns 31,518 shares of the company’s stock worth $2,434,000 after buying an additional 9,549 shares during the last quarter. Wilbanks Smith & Thomas Asset Management LLC purchased a new stake in Express Scripts in the second quarter worth $229,000. Segall Bryant & Hamill LLC increased its position in Express Scripts by 145.7% in the second quarter. Segall Bryant & Hamill LLC now owns 7,167 shares of the company’s stock worth $553,000 after buying an additional 4,250 shares during the last quarter. Finally, People s United Financial Inc. increased its position in Express Scripts by 13.1% in the second quarter. People s United Financial Inc. now owns 34,275 shares of the company’s stock worth $2,647,000 after buying an additional 3,978 shares during the last quarter. 84.89% of the stock is owned by institutional investors.
A number of analysts have issued reports on ESRX shares. BidaskClub raised Express Scripts from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. ValuEngine raised Express Scripts from a “hold” rating to a “buy” rating in a research report on Monday, September 17th. Credit Suisse Group downgraded Express Scripts from an “outperform” rating to a “neutral” rating and raised their target price for the stock from $90.00 to $96.50 in a research report on Tuesday, September 18th. Mizuho set a $101.00 target price on Express Scripts and gave the stock a “hold” rating in a research report on Monday, November 5th. Finally, Royal Bank of Canada raised their target price on Express Scripts to $94.00 and gave the stock an “outperform” rating in a research report on Monday, August 27th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $92.00.
Shares of NASDAQ ESRX opened at $98.22 on Friday. The firm has a market capitalization of $55.38 billion, a PE ratio of 13.83, a P/E/G ratio of 1.24 and a beta of 0.88. Express Scripts Holding Co has a fifty-two week low of $66.93 and a fifty-two week high of $101.73. The company has a debt-to-equity ratio of 0.63, a current ratio of 0.77 and a quick ratio of 0.65.
Express Scripts (NASDAQ:ESRX) last announced its quarterly earnings results on Wednesday, October 31st. The company reported $2.43 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.01. The company had revenue of $25.56 billion during the quarter, compared to analysts’ expectations of $25.11 billion. Express Scripts had a return on equity of 25.43% and a net margin of 4.83%. The firm’s quarterly revenue was up 3.6% compared to the same quarter last year. During the same period in the previous year, the business earned $2.51 earnings per share. As a group, equities research analysts predict that Express Scripts Holding Co will post 9.08 earnings per share for the current year.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Featured Story: Asset Allocation, Balancing Your Investments
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.